开发精神科临床可解释的神经影像学生物类型
这篇批判性综述综合功能性磁共振成像(fMRI)研究,说明其可预测重性抑郁障碍(MDD)的治疗结局,并依据个体脑回路特征匹配最有效的治疗。文中介绍一种基于6个大型生物类型回路、相对健康常模量化功能障碍的方法,个体化回路评分可预测治疗反应并调节不同治疗结局,匹配治疗有望使缓解率翻倍。
要点
- fMRI可预测MDD治疗结局并依据脑回路特征匹配个体化治疗。
- 基于6个大型生物类型回路的个体化评分可预测治疗反应或失败。
- 匹配生物类型的治疗有望使缓解率较未匹配治疗翻倍。
核心结论
- 基于fMRI的个体化回路评分可预测MDD治疗反应并匹配最佳治疗。
- 匹配患者生物类型的治疗有望使缓解率较未匹配治疗翻倍。
研究设计与样本
- 批判性综述,综合fMRI预测MDD治疗结局及解析异质性的研究。
- 介绍一种理论驱动方法,量化6个大型生物类型回路相对健康常模的功能障碍。
主要发现
- MDD初治仅33%个体达缓解,多数平均7年内经历多种治疗。
- 每次治疗失败后复发风险从50%升至90%。
- 个体化回路评分可预测治疗反应或失败,并调节不同治疗结局。
关键数值与推荐
- 个体化回路评分基于6个大型生物类型回路相对健康参考常模量化。
- 匹配生物类型的治疗有望使缓解率较未匹配治疗翻倍。
临床怎么用
- 临床可依据fMRI个体化回路评分选择匹配治疗,替代试错处方。
- 将fMRI工具转化至临床实践仍需应对关键挑战与局限性。
局限性
- 综述讨论了将fMRI工具转化至临床实践的关键挑战与局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite available treatments, major depressive disorder (MDD) remains one of the leading causes of disability across medical conditions. The current symptom-based diagnostic system groups patients with highly heterogeneous presentations, with no biomarkers to guide treatment, akin to diagnosing heart disease solely by chest pain without imaging to reveal the underlying pathology. Lacking biological guidance, clinicians rely on trial-and-error prescribing. Only 33% of individuals with MDD achieve remission in response to initial treatments, and most cycle through multiple treatments over an average of 7 years. The risk of relapse increases with each treatment failure, rising from 50% to 90%. This critical review synthesizes studies showing how functional magnetic resonance imaging (fMRI) can predict treatment outcomes and identify which treatment is most effective for an individual based on their brain circuit profile. We illustrate one such method, a theoretically informed approach that quantifies dysfunction across 6 large-scale biotype circuits, relative to healthy reference norms. The resulting personalized circuit scores serve as predictors of response or failure and as moderators of differential treatment outcomes. Matching treatment to a patient's biotype, defined by their personalized circuit scores, has the potential to double remission rates compared with unmatched treatment. We place this example in the broader context of precision imaging approaches to parsing MDD heterogeneity. We also discuss key challenges, limitations, and future directions for translating fMRI-based tools into clinical practice.
引用
- Ahn J, Foland-Ross LC, Akiki TJ, et al. Developing Clinically Interpretable Neuroimaging Biotypes in Psychiatry. Biol Psychiatry. 2025. PMID: 40930375. doi:10.1016/j.biopsych.2025.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。